The German pharmaceutical group CureVac and the British group GSK announced this Wednesday, to unite to develop the next generation of vaccine against the new variants of Covid-19.
German pharmaceutical company CureVac and British laboratory GSK decide to join forces to create a messenger RNA vaccine against new strains of the coronavirus. According to a press release published on Wednesday, February 3, this new vaccine will respond to variants already present, but also to those which would be likely to emerge during the pandemic. The work of the two laboratories is currently underway and this vaccine will be available from 2022.
A new generation of vaccine for 2021 and 2022
“We believe that the next generation of vaccine will be crucial in the ongoing fight against Covid-19”, says Emma Walmsley, CEO of GSK. The British group, the world’s leading manufacturer of vaccines, finds itself on several fronts. First with its own vaccine developed with the French Sanofi, which is behind schedule and will not be ready until the end of 2021. Pharmaceutical laboratory GSK will also help this year in the production of 100 million doses of the first generation vaccine from CureVac. In fact, the vaccine from the German pharmaceutical company is currently in phase 3 of clinical trials.
